Phase
Condition
Rheumatic Fever
Myositis
Connective Tissue Diseases
Treatment
N/AClinical Study ID
Ages 18-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Life expectancy > 1 year.
Indication to initiate prolonged glucocorticoid therapy at a dosage ≥ 15 mg/day forthe treatment of an inflammatory rheumatic disease.
Initial treatment or relapse.
Previsional treatment duration > 3 months.
Exclusion
Exclusion Criteria:
Unable to consent.
Previous corticosteroid therapy in the last 3 months at a significant dosage (> 5 mgper day).
Study Design
Connect with a study center
CHU d'Angers
Angers, 49933
FranceSite Not Available
CHRU de Brest
Brest, 29609
FranceSite Not Available
CHD Vendée
La Roche-sur-Yon, 85925
FranceSite Not Available
CH Le Mans
Le Mans, 72000
FranceSite Not Available
CH des Pays de Morlaix
Morlaix, 29672
FranceSite Not Available
CHU de Nantes
Nantes, 44093
FranceActive - Recruiting
CHU de Nantes - Service de Médecine interne
Nantes, 44093
FranceSite Not Available
CHU de Nantes - Service de Rhumatologie
Nantes, 44093
FranceSite Not Available
CHR d'Orléans
Orléans, 45067
FranceSite Not Available
<CHU de Poitiers
Poitiers,
FranceSite Not Available
CHIC Quimper
Quimper, 29000
FranceSite Not Available
Clinique St Exupéry
Toulouse,
FranceSite Not Available
CHU de Tours
Tours, 37044
FranceSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.